Views & Analysis | Perspectives on pharma industry issues

R&D

ESG considerations digitally overlain on green cityscape background

Integrate or isolate: Incorporating traditional safety-relat...

Should traditional safety considerations be treated as distinct from broader ESG frameworks, or fully integrated within them?

Sales & Marketing

What does FDA's proposed DTC advertising rule mean for pharm...

Last month, the FDA quietly added a proposed rule to the 2026 Unified Agenda that – if finalised – could make prescription drug advertising untenable.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

R&D

A practical route through regulatory uncertainty in clinical...

Organisations must remain agile and decisive across global portfolios, anticipating regulatory changes before they create clinical trial delays.

Patients

12 Questions with Kim Innes

Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry.

Market Access

How do we make patient centricity a reality?

For years, the subject of fostering direct connections with patients has been highlighted by notable figures across the healthcare and life sciences industries as a key feature to be explor

Patients

Representation in UK pharma: A progress report

Pharma understands that building equitable health services starts with building equitable institutions.

Oncology

At ESMO, three studies show promise of antibody-drug conjuga...

The American Society of Clinical Oncology, or ASCO, conference is just around the corner, but one subgroup of cancer researchers just had their own gathering, as breast cancer researchers c

Sales & Marketing

What does FDA's proposed DTC advertising rule mean for pharm...

Last month, the FDA quietly added a proposed rule to the 2026 Unified Agenda that – if finalised – could make prescription drug advertising untenable.

Sales & Marketing

Why trust is becoming pharma’s most important visibility met...

Any gap between an AI-generated answer and a product’s approved profile carries consequences for prescribing decisions and patient safety.

Digital

Building agentic AI in healthcare

Healthcare organisations can’t afford to ignore agentic AI, but they also can’t afford to deploy it without the infrastructure to use it responsibly.

Digital

Prescribed, but never filled: Why patient access is broken

Patient access is no longer just an administrative backroom function; it is a core determinant of health outcomes.

Market Access

pharmaphorum podcast Episode 270, Alice Valder Curran, Hogan Lovells

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

Market Access

Preparing for the pharma fraud enforcement surge

Here is what robust, risk-based compliance looks like in 2026.

Oncology

Key lessons from EHA 2026: Translating evidence into impact

Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care.

Oncology

Establishing ctDNA as a validated primary surrogate endpoint

Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.

Oncology

radiotherapy session for young man with cancer

Early diagnosis means little without timely treatment

Early diagnosis only changes outcomes if it is followed by timely treatment.

Patients

12 Questions with Kim Innes

Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry.

Patients

Why Britain's blood tests are only as reliable as the journe...

What happens in phlebotomy has a huge impact in pathology, and the different funding streams and management means that interests are no longer aligned

Patients

Graphic representation of human diversity

Moving beyond intent: Building more diverse clinical trials

Improving representation is not simply about increasing awareness or setting enrolment targets. It requires identifying and removing the barriers.

Integrate or isolate: Incorporating traditional safety-relat...

What does FDA's proposed DTC advertising rule mean for pharm...

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

A practical route through regulatory uncertainty in clinical...

12 Questions with Kim Innes

How do we make patient centricity a reality?

Representation in UK pharma: A progress report

At ESMO, three studies show promise of antibody-drug conjuga...

What does FDA's proposed DTC advertising rule mean for pharm...

Why trust is becoming pharma’s most important visibility met...

Building agentic AI in healthcare

Prescribed, but never filled: Why patient access is broken

Policy in Focus: What’s new with CMS drug price negotiation,...

Preparing for the pharma fraud enforcement surge

Key lessons from EHA 2026: Translating evidence into impact

Establishing ctDNA as a validated primary surrogate endpoint

Early diagnosis means little without timely treatment

12 Questions with Kim Innes

Why Britain's blood tests are only as reliable as the journe...

Moving beyond intent: Building more diverse clinical trials

Integrate or isolate: Incorporating traditional safety-relat...

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

A practical route through regulatory uncertainty in clinical...

Sources quash rumours of an AZ/BMS mega-merger

Discover a new era of healthcare panel engagement: Grounded ...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks